VIICTR
Profiles
ORIT
Pediatrics CRA
Home
About
Overview
Sharing Data
ORCID
Help
History (1)
Polymorphisms of p16, p27, p73, and MDM2 modulate response and survival of pancreatic cancer patients treated with preoperative chemoradiation.
See All Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
Polymorphisms of p16, p27, p73, and MDM2 modulate response and survival of pancreatic cancer patients treated with preoperative chemoradiation.
Polymorphisms of p16, p27, p73, and MDM2 modulate response and survival of pancreatic cancer patients treated with preoperative chemoradiation. Ann Surg Oncol. 2009 Feb; 16(2):431-9.
View in:
PubMed
subject areas
Adenocarcinoma
Adult
Aged
Aged, 80 and over
Antineoplastic Combined Chemotherapy Protocols
Carcinoma, Pancreatic Ductal
Chemotherapy, Adjuvant
Cisplatin
Combined Modality Therapy
Cyclin-Dependent Kinase Inhibitor p16
Cyclin-Dependent Kinase Inhibitor p27
Deoxycytidine
Disease Progression
DNA-Binding Proteins
Female
Humans
Male
Middle Aged
Neoadjuvant Therapy
Neoplasm Proteins
Nuclear Proteins
Pancreatic Neoplasms
Pancreaticoduodenectomy
Polymorphism, Single Nucleotide
Prognosis
Proto-Oncogene Proteins c-mdm2
Radiotherapy, Adjuvant
Survival Rate
Time Factors
Tumor Protein p73
Tumor Suppressor Proteins
authors with profiles
DONGHUI LI
ANN M KILLARY
SUBRATA SEN
CHRIS AMOS